ReviewMicroorganisms2021
Type-2 Diabetes as a Risk Factor for Severe COVID-19 Infection.
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Type 2 diabetes mellitus as a predictor of severe outcomes in COVID-19 - a systematic review and meta-analyses.BMC infectious diseases · 2025Pooled it
- IRE1α Is Associated with Host Lipid Biosynthesis During Human Coronavirus OC43 Infection.Viruses · 2026Article
- Temporal Trends and Disparities in Type 2 Diabetes Mellitus and Congestive Heart Failure Mortality in the United States From 1999-2020: A CDC WONDER Analysis.Health science reports · 2026Article
- Functional Annotation of GWAS Loci Using Public Transcriptome and Epigenome Datasets Reveals Non-Coding Genes and Regulatory Elements Which May Contribute to BMI.International journal of molecular sciences · 2026Article
- The length of hospital stay in COVID-19 patients using pre-hospital metformin at a Saudi tertiary hospital: a retrospective cohort study.BMC infectious diseases · 2026Article
- Clinical characteristics of Chinese diabetic patients and their antibody responses to Omicron subvariants.Frontiers in immunology · 2026Article
- Development and validation of a model for early prediction of severe/critical COVID-19 in elderly patients.PeerJ · 2026Article
- SGLT2 inhibitors prevent long-COVID-associated cognitive and pain symptoms in type 2 diabetes patients.Virology journal · 2025Article
- Gut Microbiota and COVID-19: Unraveling the Gut-Lung Axis and Immunomodulatory Therapies.ACS infectious diseases · 2025Review
- Article
- Article
- Evaluating Drug Interaction Risks: Nirmatrelvir & Ritonavir Combination (PAXLOVIDPathogens (Basel, Switzerland) · 2024Article
- The Influence of COVID-19 in Glycemic Control: Predictive Value of Inflammation and Metabolic Parameters.Biomedicines · 2024Article
- Immunity and Coagulation in COVID-19.International journal of molecular sciences · 2024Review
- Independent Risk Factors and Mortality Implications of De Novo Central Nervous System Involvement in Patients Hospitalized with Severe COVID-19: A Retrospective Cohort Study.Journal of clinical medicine · 2024Article
- Exploring Therapeutic Potential of Catalase: Strategies in Disease Prevention and Management.Biomolecules · 2024Review
- Potential Risk Factors to COVID-19 Severity: Comparison of SARS-CoV-2 Delta- and Omicron-Dominant Periods.International journal of environmental research and public health · 2024Article
- Article
- Type 2 diabetes and its genetic susceptibility are associated with increased severity and mortality of COVID-19 in UK Biobank.Communications biology · 2024Article
- Pandemic-related practice changes and CVD risk management in community clinics.The American journal of managed care · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
The current outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), termed coronavirus disease 2019 (COVID-19), has generated a notable challenge for diabetic patients. Overall, people with diabetes have a higher risk of developing different infectious diseases and demonstrate increased mortality. Type 2 diabetes mellitus (T2DM) is a significant risk factor for COVID-19 progression and its severity, poor prognosis, and increased mortality. How diabetes contributes to COVID-19 severity is unclear; however, it may be correlated with the effects of hyperglycemia on systemic inflammatory responses and immune system dysfunction. Using the envelope spike glycoprotein SARS-CoV-2, COVID-19 binds to angiotensin-converting enzyme 2 (ACE2) receptors, a key protein expressed in metabolic organs and tissues such as pancreatic islets. Therefore, it has been suggested that diabetic patients are more susceptible to severe SARS-CoV-2 infections, as glucose metabolism impairments complicate the pathophysiology of COVID-19 disease in these patients. In this review, we provide insight into the COVID-19 disease complications relevant to diabetes and try to focus on the present data and growing concepts surrounding SARS-CoV-2 infections in T2DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.